BioScrip, Inc. (NASDAQ:BIOS) was upgraded by equities research analysts at ValuEngine from a “sell” rating to a “hold” rating in a report released on Thursday.

Several other research analysts have also commented on the stock. Barrington Research raised their price objective on shares of BioScrip to $3.50 and gave the company an “outperform” rating in a research note on Monday, June 26th. Zacks Investment Research raised shares of BioScrip from a “sell” rating to a “hold” rating in a research note on Wednesday, June 28th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $3.50.

BioScrip (BIOS) traded down 0.34% during midday trading on Thursday, reaching $2.93. 834,795 shares of the company’s stock traded hands. The company’s market capitalization is $354.48 million. BioScrip has a 1-year low of $0.98 and a 1-year high of $3.43. The firm’s 50-day moving average is $2.17 and its 200-day moving average is $1.70.

BioScrip (NASDAQ:BIOS) last announced its earnings results on Thursday, May 4th. The company reported ($0.16) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by $0.04. The business had revenue of $217.80 million for the quarter, compared to the consensus estimate of $230.23 million. BioScrip’s revenue for the quarter was down 8.7% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.17) earnings per share. Analysts forecast that BioScrip will post ($0.38) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This article was first posted by American Banking News and is the property of of American Banking News. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at https://www.americanbankingnews.com/2017/07/16/bioscrip-inc-bios-upgraded-to-hold-at-valuengine.html.

Several hedge funds and other institutional investors have recently bought and sold shares of BIOS. Gilder Gagnon Howe & Co. LLC acquired a new position in BioScrip during the first quarter valued at approximately $7,422,000. FMR LLC raised its position in BioScrip by 3,489.1% in the fourth quarter. FMR LLC now owns 3,529,795 shares of the company’s stock valued at $3,671,000 after buying an additional 3,431,447 shares during the last quarter. California Public Employees Retirement System boosted its stake in shares of BioScrip by 37.5% in the first quarter. California Public Employees Retirement System now owns 663,700 shares of the company’s stock valued at $1,128,000 after buying an additional 181,000 shares during the period. State Street Corp boosted its stake in shares of BioScrip by 10.6% in the fourth quarter. State Street Corp now owns 1,456,697 shares of the company’s stock valued at $1,515,000 after buying an additional 139,110 shares during the period. Finally, KCG Holdings Inc. boosted its stake in shares of BioScrip by 176.2% in the first quarter. KCG Holdings Inc. now owns 209,586 shares of the company’s stock valued at $356,000 after buying an additional 133,715 shares during the period. 83.06% of the stock is owned by institutional investors and hedge funds.

BioScrip Company Profile

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for BioScrip Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip Inc. and related companies with MarketBeat.com's FREE daily email newsletter.